Cardiol Therapeutics Inc Class A (CRDL)vsNovartis AG ADR (NVS)

CRDL

Cardiol Therapeutics Inc Class A

NASDAQ

$1.15

-4.17%

HEALTHCARE · Cap: $141.78M

NVS

Novartis AG ADR

NYSE

$158.83

-0.24%

HEALTHCARE · Cap: $290.96B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).

CRDL

Avoid

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.0

Piotroski: 1/9Altman Z: -14.58

NVS

Buy

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5

Piotroski: 4/9Altman Z: 1.96

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CRDL.

NVSSignificantly Overvalued (-68.7%)

Margin of Safety

-68.7%

Fair Value

$92.54

Current Price

$158.83

$66.29 premium

UndervaluedFair: $92.54Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CRDL1 strengths · Avg: 10.0/10

Debt/EquityHealth

0.0010/10

Conservative balance sheet, low leverage

NVS5 strengths · Avg: 9.4/10

Market CapQuality

$290.96B10/10

Mega-cap, among the largest globally

Return on EquityProfitability

35.1%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability

31.8%10/10

Strong operational efficiency at 31.8%

Profit MarginProfitability

22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality

$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

CRDL4 concerns · Avg: 3.5/10

Revenue GrowthGrowth

0.0%4/10

0.0% revenue growth

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Market CapQuality

$141.78M3/10

Smaller company, higher risk/reward

Profit MarginProfitability

0.0%3/10

0.0% margin — thin

NVS4 concerns · Avg: 3.3/10

Revenue GrowthGrowth

0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth

1.964/10

Grey zone — moderate risk

Debt/EquityHealth

1.223/10

Elevated debt levels

PEG RatioValuation

4.152/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : CRDL

The strongest argument for CRDL centers on Debt/Equity.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.

Bear Case : CRDL

The primary concerns for CRDL are Revenue Growth, EPS Growth, Market Cap.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

CRDL carries more volatility with a beta of 0.51 — expect wider price swings.

NVS is growing revenue faster at 0.8% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (51/100 vs 17/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cardiol Therapeutics Inc Class A

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Cardiol Therapeutics Inc., a clinical-phase biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular diseases (CVD). The company is headquartered in Oakville, Canada.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks

CRDL vs TAK CRDL vs HLN CRDL vs TEVA CRDL vs ZTS CRDL vs UTHR NVS vs TAK NVS vs HLN NVS vs TEVA NVS vs ZTS NVS vs UTHR

Want to dig deeper into these stocks?

Full CRDL Analysis →Full NVS Analysis →